1
00:00:00,000 --> 00:00:04,667
LL-37 is a human antimicrobial peptide involved in innate defense.

2
00:00:04,667 --> 00:00:11,750
Researchers also study its effects on inflammation and wound biology, which makes the story more complex

3
00:00:11,750 --> 00:00:15,250
than a natural antibiotic label.

4
00:00:15,250 --> 00:00:22,333
A phase two-b trial tested topical LL-37 alongside compression care in 148 people with difficult venous

5
00:00:22,333 --> 00:00:28,583
leg ulcers. The overall study did not find a significant healing advantage over placebo.

6
00:00:28,583 --> 00:00:33,250
An analysis performed afterward suggested a signal in larger ulcers.

7
00:00:33,250 --> 00:00:39,917
That is a reason to test a hypothesis, not to replace the study’s overall result.

8
00:00:39,917 --> 00:00:45,000
Those findings also do not establish that injected LL-37 treats infections.

9
00:00:45,000 --> 00:00:51,667
FDA highlights safety uncertainty. A molecule’s normal role in the body cannot substitute for treatment

10
00:00:51,667 --> 00:00:55,167
evidence.